Galaxy Balance

Ancient DNA can reveal how extinct species lived and evolved. New tools in genome engineering and reproductive biology may make it possible to recreate some of their traits, and to help endangered species adapt to changing environments.

Beth Shapiro, evolutionary molecular biologist and chief science officer at Colossal Biosciences, joins Galaxy Balance to discuss what de-extinction means in practice. We explore how researchers select traits from mammoth and elephant genomes, engineer many edits in elephant cells, and use different approaches for mammals and birds. Beth also explains how her team weighs animal welfare and genetic risk, why the direwolves were given light coats through a safer genetic route, and how local communities, Indigenous groups, and regulators can shape conservation plans.

The conversation covers the limits of ancient DNA, tools such as Genomorph, and the potential for technologies developed through de-extinction research to support biodiversity and conservation.

00:43 — Introduction to Dr. Beth Shapiro and the promise of de-extinction

01:55 — Beth’s path into ancient DNA and the appeal of reconstructing extinct worlds

03:31 — Why ancient DNA inspired Jurassic Park, not the other way around

04:20 — The first ancient-DNA breakthrough and the limits of recovering very old DNA

06:39 — Why mammoths became a central de-extinction target

08:50 — From early DNA sequencing to modern genomic tools

12:04 — How mammoth traits are selected from elephant and mammoth genomes

14:21 — Turning genetic differences into traits: hair, fat, ears, tails, and tusks

17:12 — Multiplex editing: making many genetic changes at once

19:29 — Genome integrity, off-target edits, and selecting healthy cell lines

24:11 — From edited cells to animals: cloning mammals and engineering birds

27:42 — The reproductive challenges of making mammoths and helping elephants

30:40 — Advancing bird genetics for dodo, moa, and conservation work

33:16 — Genetic rescue: engineering cane-toad-resistant quolls

35:31 — Regulation, local communities, and responsible phased releases

37:12 — Indigenous leadership and the moa restoration project

39:29 — Beth’s proudest achievement: expanding genetic tools for birds

44:06 — Can we restore traits without ancient DNA? The dire wolf example

48:09 — Why dire wolves will not be released into the wild

51:21 — Conservation over novelty: using genome editing to address biodiversity loss

53:49 — The biggest remaining technological hurdles

56:33 — “Playing God,” human responsibility, and shaping a biodiverse future

58:05 — Science-fiction recommendations and the enduring warning of Jurassic Park

Premature babies enter the world before many of their biological systems are ready, yet the technologies that keep them alive often separate them from their parents. Alon Metrikin-Gold, founder and CEO of NEOCare, is working to redesign neonatal care around connection.

His team developed SKINcubator, a wearable medical device intended to enable immediate and prolonged skin-to-skin care for premature and medically fragile infants. The device maintains warmth and humidity while securing the baby and supporting the lines and tubes required in intensive care.

In this episode, we explore why separation is not a neutral baseline, how physical contact affects stress regulation and development, and why parents should be treated as part of the clinical care team.

00:00 - Introduction to Skincubator Neocare and the problem of prolonged skin-to-skin care

01:11 - Alon’s background in women’s health and medical anthropology

03:03 - The key insight: separation is the artificial state

04:45 - WHO guidance versus actual NICU practice

06:14 - What parents and nurses revealed about failed skin-to-skin care

07:49 - Why extremely premature babies are so fragile

09:46 - The early engineering idea: heat and humidity from the parent’s body

10:43 - Six core design requirements for the first week of life

11:42 - What “transfer” means in practice and why it is so stressful

13:07 - Line safety, hypothermia, and why short sessions still fail

14:32 - How the device maintains heat, humidity, safety, and access

15:02 - Early clinical results and hours of skin-to-skin care achieved

16:19 - Target population and why the first days of life matter most

17:15 - Why NICU care often leaves parents unsure of their role

18:12 - How the broader system is built around separation

19:10 - Why skin-to-skin care is not just “nice,” but medically significant

21:06 - Human connection as something technology should support, not replace

22:04 - FDA breakthrough designation and what it means

23:32 - Why better documentation of skin-to-skin care matters

24:31 - How the device becomes a catalyst for protocol change

26:35 - The biology of stress reduction, cortisol, and stabilization

28:03 - Skin-to-skin care as preventative medicine and neurodevelopment support

30:28 - Maternal and infant benefits, including feeding and sensory regulation

31:25 - Designing as a producer, not an engineer, and listening to nurses

32:47 - Building for two user groups at once: parents and nurses

34:44 - How aesthetics, regulation, business model, and manufacturing all connect

36:29 - Funding the company with angels and seed capital

37:25 - Clinical expansion plans in Europe, Germany, Canada, Poland, Australia, and the US

38:10 - Safety, feasibility, and randomized trials focused on increased contact time

39:34 - Future outcome studies: baby, parent, nurse, hospital, and ROI measures

41:50 - The long-term roadmap: connected care from delivery to discharge

43:48 - Quantifying skin-to-skin barriers and the challenge of measurement

44:46 - Why parents occupy both patient and labor roles in the NICU

46:36 - Three strategic arcs: discharge, parent engagement, and low-resource settings

47:14 - Parenting, stress, and the emotional reality of the NICU

49:32 - Reimbursement, leave policies, and institutional barriers for families

55:13 - Advice for medical device founders: solve the problem, not the idea

56:42 - Why medical devices require technology, regulatory, and business model alignment

57:30 - Collecting data early to validate the next step

58:59 - Alon’s science fiction and urban fantasy recommendation

What happens when scientists rewrite the genetic code that nearly all life on Earth shares?

Dr. Akos Nyerges, a genome engineer and independent research group leader at Harvard Medical School, joins Galaxy Balance to explore the emerging world of synthetic genomes. His lab is engineering bacteria with altered genetic codes that can resist viral infection, restrict the exchange of genetic information, and incorporate chemical building blocks beyond biology’s standard 20 amino acids.

Akos explains how these genetic firewalls could make engineered organisms safer for drug delivery, biomanufacturing, and environmental applications. We examine why large-scale genome rewriting often produces sick cells, how multi-omics can reveal hidden errors such as accidental promoters and mistranslated proteins, and how his team restored recoded bacteria to near-normal fitness.

The conversation also explores AI-assisted genome design, cloud laboratories, engineered living medicines, horizontal gene transfer, the risks of mirror life, and the regulatory frameworks needed as synthetic biology moves toward increasingly ambitious forms of life.

Could we create organisms isolated from the rest of nature? Can evolution overcome even our strongest genetic firewalls? And how close is modern genome engineering to becoming science fiction made real?

00:00 Introduction
01:16 Akos’s Path to Synthetic Biology
03:59 Engineering the Genetic Code
05:45 Three Goals for Synthetic Biology
09:16 Controlling Horizontal Gene Transfer
11:11 Building a Genetic Firewall
13:39 Toxicity of Recoded tRNAs
14:26 Drug Delivery and Bioremediation
16:22 Solving the Fitness Problem
18:35 Measuring Real Biological Fitness
20:13 Testing Virus Resistance
23:37 Why the Genetic Code Is Universal
26:42 From Recoding to Applications
28:52 Debugging Genomes With Multiomics
31:15 Hidden Bugs in Genome Design
35:33 AI for Genome Design
37:51 Can LLMs Recode Genomes?
40:06 Building Local AI Compute
42:18 Cloud Labs and CROs
45:52 From Lab to Commercial Use
47:26 Translational Research and IP
48:44 Expanding Biology’s Chemical Alphabet
49:59 Ethics, Biosafety, and Regulation
53:23 The Risks of Mirror Life
57:37 When Science Fiction Becomes Real
58:33 Closing and Hiring Announcement

If the universe contains billions of potentially habitable worlds, where is everybody?

Dr. Terry Adair, author of Where Are the Little Green Men? The Adair Hypothesis, joins Galaxy Balance to examine the Fermi paradox through the lens of energy. His hypothesis proposes that an advanced technological civilization requires access to an abundant, dense, storable, transportable, and scalable energy supply.

The conversation traces Earth’s energetic evolution from hydrothermal chemistry and photosynthesis to fire, fossil fuels, nuclear fission, and fusion. Terry explains how photosynthesis enabled complex life while also creating the ancient reserves of coal, oil, and natural gas that eventually powered industrial civilization. He argues that this unlikely sequence may represent a series of filters preventing intelligent life elsewhere from producing detectable technology or reaching other stars.

We also explore the Drake equation, abiogenesis, the evolution of complex life, the technological limitations of ocean worlds, the challenges surrounding red dwarf stars, and the laws of thermodynamics that constrain every possible civilization. Terry outlines how fusion energy could eventually enable plasma drives, antimatter production, and spacecraft capable of reaching a meaningful fraction of the speed of light.

The episode closes with an optimistic vision of humanity’s long-term future. If we continue expanding our scientific knowledge and energy capabilities, humans may eventually become the interstellar visitors that other civilizations look toward the sky hoping to find.

00:00 - Why the Fermi paradox belongs at the center of this conversation

03:37 - How Adair’s background led him to an energy-based hypothesis

04:20 - What the Fermi paradox actually means

08:14 - Drake equation, exoplanets, and the Great Filter

10:23 - Why the Drake equation is a framework, not an exact answer

11:47 - Why abiogenesis and intelligence are not the same question

13:29 - Earth’s evolutionary milestones from microbes to technology

15:10 - Why photosynthesis is the breaking point in life’s history

18:28 - The difference between abundant energy and usable energy

21:49 - Endosymbiosis, mitochondria, and the energy jump in complex life

23:51 - Why CO2 is the raw material behind plant structure

26:19 - How biomass became coal, oil, and natural gas

29:25 - Where uranium and thorium come from

31:46 - Why nuclear fusion is central to future civilization

33:34 - Entropy, disorder, and why perpetual motion fails

38:03 - The limits of fossil fuels and the case for nuclear fission

40:02 - Weapons, waste, and why small modular reactors matter

43:20 - The Adair Hypothesis, defined

44:14 - Fire as humanity’s first technology

47:27 - The photosynthetic trap and why fossil fuels changed civilization

49:58 - How much energy humanity has burned in 200 years

51:21 - Could an aquatic species build technology without fire?

52:32 - From Democritus to quarks: what matter really is

56:22 - Why energy access on Earth is still an equity issue

58:51 - Antimatter, plasma drives, and propulsion limits

62:47 - Why fusion-powered travel is a 300 to 400 year project

64:21 - Humans as the future “little green men”

65:21 - Why Star Wars is Adair’s favorite science fiction reference

What if we could design a medicine for a single person?

Casey McPherson was a musician and songwriter when his daughter Rose was diagnosed with an ultra-rare neurogenetic disease. There was no approved treatment and no clear path forward. Rather than accepting that answer, Casey began learning genetics, building a network of scientists, and ultimately creating the infrastructure needed to develop a treatment for his daughter.

Today, Casey is the CEO and co-founder of Alpha Rose Therapeutics, where his team is working to make individualized genetic medicine scalable. Their approach combines antisense oligonucleotides, patient-derived stem cells, AI-guided therapeutic design, automation, and a new economic model for diseases that traditional drug development often leaves behind.

We discuss how Alpha Rose reduced a therapeutic amenability analysis that once took months to just minutes using AI, why Casey believes drug development should eventually be approved as a repeatable process rather than one drug at a time, and how point-of-care synthesis could allow personalized genetic medicines to be produced rapidly for individual patients.

We also explore autonomous laboratories, AI scientists, patient-derived iPSCs and brain organoids, the economics of rare disease, genetic enhancement, and a future of medicine that looks increasingly like the sick bay of Star Trek: understand the unique biology of the patient, design the intervention, synthesize it, and treat them.

Casey's story raises a much bigger question. Are rare diseases really rare, or are they the first glimpse of a future where every disease becomes individualized?

00:00 - Casey McPherson’s path from musician to biotech founder

01:38 - Childhood curiosity: music, programming, electronics, and biology

04:16 - Rose’s diagnosis and the end of the traditional care pathway

07:46 - Learning the problem was bigger than one child

09:59 - Why a foundation and ecosystem had to come first

11:27 - Why Rare Labs was built as a modality agnostic discovery lab

12:24 - Why antisense oligonucleotides made sense for Rose

13:22 - Designing and filtering thousands of ASO candidates

15:13 - Building patient-specific iPSCs and brain organoids

17:25 - Why animal models are mainly a safety tool

20:06 - Why Alpha Rose became a public benefit corporation

23:22 - Regulatory strategy and the path toward a small patient trial

27:35 - How Casey learned drug development by doing

30:30 - The AI amenability study workflow for new patients

33:24 - Turning a rough AI prototype into a validated internal tool

35:34 - Using the tool on every new drug and patient case

36:31 - Why speed matters when families are waiting on treatment

37:54 - Rare disease as a business model problem, not just a science problem

43:02 - The next decade of individualized medicine

44:27 - Process approval and point-of-care drug synthesis

46:34 - Beyond rare disease: enhancement and broader applications

48:24 - Why children’s health is so underfunded

51:20 - Why precision medicines can lower development risk

53:33 - Robotics and the fully automated lab of the future

55:46 - Renee, conversational AI, and the scientist-as-assistant future

56:54 - Science fiction influence and the Star Trek medicine model

59:50 - Advice for families and scientists facing genetic disease

1:02:21 - Closing thoughts on individualized disease

Could life be using quantum physics to sense the world, regulate cellular processes, and respond to magnetic fields?

Clarice Aiello is a quantum engineer, Chair of the Board and Chief Scientific Officer at the Quantum Biology Institute, and the founder of the former Quantum Biology Tech Lab at UCLA. Her research explores whether living systems harness quantum phenomena once considered too fragile to survive within warm, noisy cells.

In this episode of Galaxy Balance, Clarice explains quantum tunneling, superposition, entanglement, and decoherence through the lens of biology. We discuss how electrons inside proteins may function as nature-made quantum sensors, how weak magnetic fields can influence cellular behavior, and whether engineered magnetic fields could eventually support wound healing, regeneration, and other forms of electromagnetic medicine.

Clarice also describes the evidence that birds may use quantum sensing to navigate, why nature could teach us to build better quantum technologies, and how altered magnetic environments may affect organisms traveling to the Moon or Mars. We explore the scientific standards needed to move quantum biology into the mainstream, the limits of current evidence, and the possibility of creating a Star Trek-style tricorder that interacts with biology through precisely designed magnetic fields.

The conversation closes with quantum literacy, science fiction, interdisciplinary research, and Clarice’s advice for the next generation of scientists entering one of biology’s strangest emerging frontiers.

0:00 Clarice Aiello’s background and why quantum biology matters
7:12 The long-term vision for magnetic-field-based therapeutics
10:30 Why the field still lacks depth, breadth, and standards
15:30 What quantum physics is, in plain language
19:01 Superposition explained with dimmer-switch logic
26:19 Why decoherence limits quantum effects in warm, wet cells
29:27 What counts as evidence for quantum biology today
32:24 Skepticism about entanglement, microtubules, and consciousness claims
34:37 The double-slit experiment and why observation is often misunderstood
37:11 Mars, the Moon, and why magnetic fields may matter for colonization
41:37 How weak magnetic fields may work at the protein level
44:36 Spin-dependent chemical reactions and biological branching
53:14 Why Clarice thinks nature is effectively a quantum engineer
58:13 Science fiction, Recursion, and what it gets right and wrong about observation
59:05 Why quantum literacy should be part of basic education

00:00 - Introduction to Lily and GLife’s vision for data-driven dermatology

01:20 - Lily’s scientific background

02:43 - Breakthroughs from single-cell atlases

03:50 - The motivation behind founding GLife

04:50 - The importance of treating skin as a foundational organ

05:48 - Discovery of key molecular drivers of aging

06:22 - Challenges of fundraising

07:45 - The novel approach to rejuvenating hair loss through targeted messenger RNA treatments

08:53 - How treatments will be delivered via microneedles and micro patches

09:32 - The potential to alter hair color and explore cosmetic applications

10:06 - Balancing platform discovery engines with the development of first-in-class therapeutics

10:43 - The comprehensiveness of the skin atlas and addressing genetic diversity

11:39 - Technical challenges of capturing skin’s cellular heterogeneity and stem cell populations

12:50 - The importance of isoforms and deep sequencing in understanding gene functions

13:16 - Short-lived messenger RNA as a safe, reversible treatment modality

14:55 - Safety considerations and toxicity management

16:01 - Biodistribution studies and local micro-needle delivery safety

17:00 - Next steps towards clinical trials and regenerative therapies for hair loss

18:08 - The role of big data and omics in understanding skin disorders and aging

19:04 - The significance of isoforms in skin biology and gene function

20:13 - Endogenous vs. modified messenger design for safety and efficacy

21:32 - Potential for multi-gene delivery to enhance hair regrowth and color restoration

22:22 - Conception of patches that work with existing hair without shaving

23:38 - Targeting broad hair loss types and the concept of root causes

24:47 - Modeling hair loss with animal models and regulatory considerations

25:48 - Regulatory perspectives on non-animal models and validation strategies

26:34 - The interplay between genetic and environmental causes of skin aging

27:54 - The biological hub role of specific transcription factors in stress and aging

29:10 - The future of skin biomarkers for diagnosis and personalized health monitoring

30:18 - Leveraging AI’s data integration and precision medicine in dermatology

32:32 - The impact of protein isoforms and post-translational modifications in skin treatment

34:47 - Interest in peptides, small molecules, and biohacking trends for skin health

36:03 - Collaboration between wet labs, computational teams, and clinical partners

36:36 - The significance of internal naming conventions in research and development

37:28 - The high-throughput screening process for key transcription factors

38:13 - Strategies for overexpressing target genes in therapeutic design

39:00 - AI’s role in accelerating discovery and development pipelines in biotech

40:39 - Addressing data quality, heterogeneity, and integration challenges in big datasets

44:12 - Envisioning personalized skincare driven by genomics and AI

44:56 - The inspiring concept that ancient technologies now seem like magic

45:24 - Challenges in bringing novel dermatological treatments through trials and regulation

47:42 - The evolving role of AI in drug quality control and documentation

48:11 - Unique advantages of Lily’s targeted mRNA approach over other modalities

49:22 - Using skin as a model system for broader human biology insights

50:28 - Perspectives on epigenetic reprogramming and cellular re-differentiation

51:22 - Fundraising experiences and strategic positioning for biotech development

52:21 - The influence of science fiction, especially “Three Body Problem” and “Interstellar,” on Lily’s vision

54:24 - Advice to young scientists: read widely, think deeply, and dream big

What does it take to bring new chemistry to life?

In this episode of Galaxy Balance, Cory Smith speaks with Aditya Kunjapur, Associate Professor of Chemical and Biomolecular Engineering at the University of Delaware, about genetic code expansion, non-standard amino acids, engineered microbes, and the future of synthetic biology.

Aditya’s lab explores how biology can be programmed to biosynthesize chemical groups that are rare or absent in nature, install those new building blocks into proteins, and make microbial survival depend on synthetic chemistry. The conversation moves from his early path through energy and chemical engineering, to his time in George Church’s lab, to the founding of Nitro Biosciences and the use of expanded genetic codes for next generation vaccine platforms.

They discuss how non-standard amino acids can act as chemical flags for the immune system, how live microbes could produce antigens inside the body, and why genetic code expansion may open new approaches to vaccines, biocontainment, agriculture, environmental engineering, and planetary protection.

The episode also explores synthetic auxotrophy, engineered microbial dependence, plant controlled microbial survival, plastic degradation, agricultural probiotics, bioenergy, AI tools for non-standard amino acids, and the science fiction lessons behind containment, from Jurassic Park to modern AI.

This is a conversation about rewriting the language of life, not only to understand biology, but to give it new chemistry, new safeguards, and new possibilities.

Timestamps:

00:00 - Engineering microbes for space: Bacillus subtilis and biological containment
02:28 - Aditya’s pathway into synthetic biology and innovative chemistry
05:46 - Transitioning from industry internships to academia and entrepreneurship
10:16 - Founding Nitro Biosciences: balancing entrepreneurship with academic research
16:31 - Genetic code expansion and its potential to elicit immune responses
22:41 - The scarcity and potential of non-standard amino acids in life
27:26 - Detecting extraterrestrial life and the shared building blocks of biology
36:49 - Synthetic oxytrophy and microbial biocontainment strategies
44:01 - Reducing herbicide reliance with engineered microbes in agriculture
52:53 - Computational tools and AI for non-standard amino acid research
54:53 - Bioenergy and sustainability: bio-catalysis innovations
59:08 - How science fiction influences bioengineering and AI safety considerations

Erik Aznauryan, CEO and co-founder of HarborSite, joins Galaxy Balance to explore the next frontier of genome engineering: moving beyond small edits and toward precise, large-scale DNA insertion. Erik traces his path from Armenia and medical school to Europe, the Church Lab, and eventually founding HarborSite with a mission to make gene insertion safer, more durable, and more programmable.

The conversation dives into recombinases, safe harbor sites, payload size limits, delivery vehicles, in vivo validation, AI-driven protein engineering, and the therapeutic promise of inserting full genes or even entire genetic programs into the genome. Cory and Erik also discuss rare disease, cell therapy, skin and liver targeting, regulatory bottlenecks, animal models, funding shifts in biotech, and the long-term possibility of human enhancement in an age of AI.

At the edge of science fiction and translational medicine, this episode asks what becomes possible when genome engineering evolves from editing biology to writing biology at scale

00:00 — The North Star for genome engineering

00:36 — Introduction to Erik and HarborSite

01:39 — Erik’s path into science

02:36 — Early fascination with cloning and genome engineering

03:21 — Cory’s own early inspiration

04:03 — Why genome engineering matters

05:24 — Ethical questions around germline engineering

06:37 — Why early-stage intervention matters

07:51 — Technical progress and disease-specific editing

09:25 — Why HarborSite was founded

10:50 — Recombinases as the core technology

12:15 — Engineering recombinases for new DNA targets

13:12 — Novel genomic safe harbors

14:18 — How safe harbors are selected and validated

15:36 — How much target specificity can be changed?

16:36 — Why lifelong expression matters

17:29 — Testing durability in culture and in vivo

18:26 — The appeal of the albumin locus

19:15 — Endogenous production of biologics

20:59 — Startup challenges and fundraising

22:28 — Why LabCentral is valuable

23:07 — AI BioHub and large proprietary datasets

24:08 — AI’s role in model development

25:11 — Practical uses of AI in biotech startups

26:51 — How the team handles data analysis

27:56 — What the therapeutic product looks like

28:52 — First target tissues: liver and T cells

30:27 — Testing off-target integration

31:27 — Balancing specificity and efficiency

32:24 — Lessons from CAR-T and random integration

33:40 — Why recombinase systems may be safer

34:39 — Payload size and delivery constraints

35:35 — Delivery strategies under consideration

38:09 — Simpler donor DNA formats

39:38 — Platform company and therapeutic company

40:59 — The key milestone: in vivo validation

41:48 — HarborSite’s pre-seed raise

43:05 — How VC expectations have shifted

44:26 — Choosing the right in vivo model

46:22 — The continued importance of mouse studies

48:23 — Global regulatory differences

50:10 — Science funding in the U.S.

52:40 — Synthetic biology in space

54:34 — Enhancement and self-directed health

57:40 — Science fiction and inspiration

59:34 — Advice for young scientists

60:31 — Closing remarks

Max Rye and Evan Appleton of Intertwined Bio join Galaxy Balance to explore one of the boldest ideas in modern biology: borrowing nature’s most extreme traits and translating them into human health.

From horses that resist liver cirrhosis to naked mole rats, bowhead whales, radiation resistant organisms, hibernating animals, and the future of humans in space, this conversation asks what becomes possible when evolution itself becomes a design library. Max and Evan explain how Intertwined Bio is using synthetic biology, gene editing, AI, virtual macrophages, and agentic systems to identify traits from extraordinary animals and test whether those adaptations can be engineered into human cells.

We discuss liver fibrosis, DNA damage repair, innate immune engineering, longevity, space radiation, de extinction, Colossal Biosciences, the future of virtual cells, and the ethical line between therapy and enhancement.

This is a conversation about turning science fiction into biology.

00:00 - Introduction to Intertwined Bio and their innovative approach

01:01 - The origins and motivations of Max and Evan in biotech

04:56 - Scientific foundation: Borrowing traits from long-lived and resilient animals

07:16 - Why now? Recent technological advances enabling these innovations

10:46 - Role of AI in understanding complex biological systems and virtual cell modeling

14:17 - Delivery strategies for genetic modifications in humans

18:19 - Regulatory pathways and ethical boundaries in gene editing

22:25 - The potential of junk DNA variants and regulatory engineering

27:09 - The potential impact on sports animals and broader applications

31:12 - Industry landscape, collaboration, and competition

33:21 - Building a startup: team dynamics, trust, and early steps

35:58 - Insights on other biotech ventures like AstroMech and their directions

38:39 - Space applications: radiation resistance, hibernation, and life support systems

43:01 - Prioritizing targets using AI and high-throughput screening

48:31 - Broader prospects: aging, longevity, and the OZEMPIC effect

52:44 - Focus on innate immune system engineering and virtual cell development

57:15 - Strategies for macrophage gene editing and cell type targeting

1:01:36 - Bottlenecks in lab throughput and cell growth limitations

1:04:30 - The influence of science fiction on biotech innovation and ethical outlooks

1:06:14 - Closing thoughts: science fiction as inspiration and the rapid transition of ideas into reality